UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 31, 2011 (May 25, 2011)
Endo Pharmaceuticals Holdings Inc.
(Exact name of registrant as specified in its charter)
Delaware | 001-15989 | 13-4022871 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) | ||
100 Endo Boulevard, Chadds Ford, PA | 19317 | |||
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code (610) 558-9800
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.07 | Submission of Matters to a Vote of Security Holders. |
(a) On May 25, 2011, Endo Pharmaceuticals Holdings Inc. held their Annual Meeting of Shareholders.
(b) Shareholders voted on the matters set forth below.
1. | The nine nominees for election to the Board of Directors of the Company (representing all of the members of the Board of Directors of the Company) were elected, each for a one-year term to serve until the next Annual Meeting of Stockholders or until their successors are duly elected and qualified: |
Nominee | Votes For | Abstentions | Broker Non Votes |
|||||||||
John J. Delucca |
100,635,944 | 1,863,187 | 4,876,025 | |||||||||
David P. Holveck |
101,842,921 | 656,210 | 4,876,025 | |||||||||
Nancy J. Hutson, Ph.D. |
100,639,855 | 1,859,276 | 4,876,025 | |||||||||
Michael Hyatt |
101,396,084 | 1,103,047 | 4,876,025 | |||||||||
Roger H. Kimmel |
101,414,416 | 1,084,715 | 4,876,025 | |||||||||
William P. Montague |
101,916,405 | 582,726 | 4,876,025 | |||||||||
David B. Nash, M.D., M.B.A. |
101,893,486 | 605,645 | 4,876,025 | |||||||||
Joseph C. Scodari |
100,595,113 | 1,904,018 | 4,876,025 | |||||||||
William F. Spengler |
100,642,024 | 1,857,107 | 4,876,025 |
2. | The proposal to ratify the appointment of Deloitte & Touche LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2011was approved based upon the following votes: |
Votes for approval |
104,962,799 | |||
Votes against |
2,232,843 | |||
Abstentions |
179,514 | |||
Broker non-votes |
0 |
3. | The proposal to approve, on an advisory basis, named executive officer compensation was approved based upon the following votes: |
Votes for approval |
91,630,932 | |||
Votes against |
5,177,098 | |||
Abstentions |
5,691,101 | |||
Broker non-votes |
4,876,025 |
4. | The proposal on the frequency of future advisory votes on executive compensation received the following votes: |
For one year |
78,601,035 | |||
For two years |
309,714 | |||
For three years |
17,922,808 | |||
Abstentions |
5,665,574 | |||
Broker non-votes |
4,876,025 |
See Item 5.07(d) below.
5. | The proposal to approve the Companys Employee Stock Purchase Plan was approved based upon the following votes: |
Votes for approval |
94,874,637 | |||
Votes against |
1,906,294 | |||
Abstentions |
5,718,200 | |||
Broker non-votes |
4,876,025 |
6. | Other such matters as may properly come before the Annual Meeting or any adjournment or postponement thereof |
None.
(c) Not applicable.
(d) Based upon the results set forth in item (b) (4) above, the Board of Directors has determined that advisory votes on executive compensation will be submitted to shareholders on an annual basis.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
ENDO PHARMACEUTICALS HOLDINGS INC. | ||
(Registrant) | ||
By: | /S/ CAROLINE B. MANOGUE | |
Name: | Caroline B. Manogue | |
Title: | Executive Vice President, Chief Legal Officer & Secretary |
Dated: May 31, 2011